A trial update dated October 23, 2026 reports on a study titled "First-in-man Trial to Assess the Safety, Performance and Clinical Benefit of the TRICENTO G2 Transcatheter Valve System for Tricuspid Regurgitation," registered as NCT07536724. The trial status is listed as recruiting, with the phase marked as not applicable.
Nesiritide, which has an unapproved research regulatory status, is noted in connection with this trial record. The update does not provide results, efficacy data, or safety findings at this time, as the study remains in the recruiting stage.
No additional details regarding trial design, patient population, or endpoints were included in this update beyond the title, status, and phase. The record is publicly listed on ClinicalTrials.gov under the identifier NCT07536724 for those seeking the official trial listing.
As with any actively recruiting first-in-man study, outcomes and safety data are not yet established and should not be assumed. Readers interested in background on nesiritide, including its current regulatory status, can consult the compound overview for further context.